Polyrizon (PLRZ) stock has been in a sharp uptrend ever since the development-stage biotech firm reported breakthrough preclinical data for its proprietary intranasal naloxone hydrogel.
In a recent press release, the Israeli company said its naloxone hydrogel outperformed an intranasal spray currently in the market, a major advantage for real-world opioid overdose emergencies.
